Johnson & Johnson COVID-19 vaccine trials have become the second candidate hopeful being paused due to the occurrence of an unexplained illness during the trials.
This is the Phase 3, 60,000 participant late-stage trial in multiple countries testing the safety and efficacy of a single dose vs a placebo that has been put on hold and enrollment is also halted citing an unexplained illness in the trial; a two-dose regimen is being tested in a separate trial.
According to the company, such pauses are not uncommon in clinical trials, and they said that there would be a careful review of all of the medical information before deciding how to proceed or whether to restart the study.
